What changed in Krystal Biotech, Inc.'s latest annual report
In the year ended 31 Dec 2025, Krystal Biotech, Inc.'s revenue rose 33.9% to USD 389.13m, from USD 290.51m; net income rose 129.7% to USD 204.83m, from USD 89.16m; cash and cash equivalents rose 43.9% to USD 496.30m, from USD 344.87m.
Year ended 31 Dec 2025. Source: 10-K filed 17 Feb 2026, read it on SEC EDGAR.
USD 290.51m to USD 389.13m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 290.51m | 389.13m | Up 33.9% |
| Net income | 89.16m | 204.83m | Up 129.7% |
| Total assets | 1.06bn | 1.33bn | Up 26.3% |
| Total liabilities | 109.46m | 114.23m | Up 4.4% |
| Cash and cash equivalents | 344.87m | 496.30m | Up 43.9% |
| Shareholders' equity | 946.38m | 1.22bn | Up 28.9% |
Questions people ask
Did Krystal Biotech, Inc.'s revenue grow last year?
Revenue grew 33.9%, from USD 290.51m to USD 389.13m in the year ended 31 Dec 2025.
Is Krystal Biotech, Inc. profitable?
Yes. Net income was USD 204.83m in the year ended 31 Dec 2025. The year before: USD 89.16m.
How much cash and debt does Krystal Biotech, Inc. have?
At its latest year end (31 Dec 2025), Krystal Biotech, Inc. reported cash and cash equivalents of USD 496.30m.
Where do these numbers come from?
From Krystal Biotech, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Krystal Biotech, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%